HC toxin for treating advanced stage neuroblastoma
Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required. Especially N-myc amplified neuroblastoma cells shall be targeted.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles

Using Electroencephalography to Improve Language Disorder Treatments
Researchers work towards an inexpensive and portable solution for treating aphasia Electroencephalography (EEG) may offer a more accessible alternative to functional magnetic resonance imaging (fMRI) for guiding transcranial direct current…

Measuring Life on Earth from Space: A Global Research Project
Measurements and data collected from space can be used to better understand life on Earth. An ambitious, multinational research project funded by NASA and co-led by UC Merced civil and…

Best Approach for Stroke in Medium-Sized Blood Vessels Identified
Calgary’s Stroke Program advancing science to improve care, treatment and outcomes for patients University of Calgary’s Hotchkiss Brain Institute researchers with the Calgary Stroke Program at Foothills Medical Centre revolutionized…